SRPX2 Emerges as a Master Switch Behind Colorectal Cancer Spread and Immune Evasion

A single secreted protein may explain why some colorectal tumors spread relentlessly and shrug off modern immunotherapy. In a study published in Cell Death Discovery, researchers report that sushi repeat-containing protein X-linked 2, or SRPX2, acts as an upstream driver of metastasis in colorectal cancer by physically stabilizing the TGF-beta receptor 2 and thereby amplifying one of the most potent pro-metastatic signaling pathways in human biology. The finding, drawn from multi-omics profiling of metastatic colorectal cancer datasets and validated across cell, animal, and clinical tissue models, positions SRPX2 as both a biomarker of aggressive disease and a candidate therapeutic target for the microsatellite stable subtype of colorectal cancer, a patient group with notoriously few effective options.

Colorectal cancer remains one of the most common and lethal malignancies worldwide, and the dominant cause of death is not the primary tumor itself but its spread, most frequently to the liver. Metastatic disease is particularly refractory in tumors classified as microsatellite stable, which lack the high mutation burden that makes microsatellite unstable tumors responsive to immune checkpoint inhibitors such as anti-PD-1 antibodies. For these patients, targeted therapies and immunotherapies have delivered limited benefit, and the biological programs that allow tumor cells to detach, invade, survive in circulation, and colonize distant organs have remained only partially mapped. Understanding the molecular switches that govern these programs is therefore a central goal of translational oncology.

At the heart of the new study is the epithelial–mesenchymal transition, a developmental program that cancer cells hijack to abandon their epithelial identity, characterized by tight cell–cell adhesion and polarity, and adopt a motile, mesenchymal state better suited for invasion and dissemination. Closely intertwined with EMT is the remodeling of the extracellular matrix, the protein scaffold surrounding cells that must be degraded and restructured for tumor cells to breach tissue boundaries. The transforming growth factor beta pathway is a canonical inducer of both processes: when TGF-beta ligands engage their receptors at the cell surface, a phosphorylation cascade involving SMAD proteins and non-SMAD branches rewrites gene expression to favor mesenchymal traits, matrix deposition, and immunosuppressive microenvironments. Yet while the downstream effects of TGF-beta signaling in metastasis are well documented, the upstream mechanisms that determine why this pathway becomes hyperactivated in some tumors and not others have remained elusive.

To identify such upstream regulators, the research team, led by investigators at the Seventh Affiliated Hospital of Sun Yat-sen University in Shenzhen, Renmin Hospital of Wuhan University, and Sun Yat-sen University Cancer Center in Guangzhou, performed a multi-omics analysis of metastatic colorectal cancer datasets. Rather than examining gene expression in isolation, they integrated transcriptomic data with information on tumor microenvironment composition, allowing them to search for genes whose activity correlated not only with aggressive clinical behavior but also with the abundance of mesenchymal and stromal features within tumors. From this screen, SRPX2 emerged as the top candidate gene associated with aggressive progression and resistance to immunotherapy.

SRPX2 is a secreted, sushi repeat domain-containing protein whose name reflects its location on the X chromosome. Previously studied in contexts ranging from angiogenesis to neurological disease, it had not been established as a central regulator of TGF-beta signaling in cancer. The new work changes that picture substantially. Through a series of biochemical experiments, the researchers demonstrated that SRPX2 binds directly to TGFBR2, the type II receptor that initiates the canonical TGF-beta signaling cascade upon ligand binding. This interaction stabilizes the receptor protein, preventing its degradation and effectively raising the number of functional receptors displayed on the tumor cell surface. The consequence is a sensitized, hyperresponsive TGF-beta pathway: signals that would otherwise be moderate become amplified, driving stronger and more sustained activation of the EMT and extracellular matrix remodeling programs.

The functional consequences of this molecular wiring were tested rigorously in experimental models. When the researchers ablated SRPX2, either genetically or through knockdown approaches, colorectal cancer cells lost key mesenchymal characteristics, and their capacity for invasion diminished. More strikingly, in animal models of colorectal cancer, SRPX2 depletion markedly suppressed the formation of liver metastases, the single most lethal manifestation of the disease. Conversely, elevated SRPX2 expression in tumor cells promoted the mesenchymal phenotype and enhanced metastatic behavior, consistent with its role as a driver rather than a passive correlate of disease progression.

Beyond metastasis itself, the study uncovered a second, immunologically significant role for the SRPX2–TGF-beta axis. The tumor microenvironment of SRPX2-high tumors was characterized by increased mesenchymal abundance, a stromal state long associated with immune exclusion and immunosuppression. Dense, fibrotic extracellular matrix and mesenchymal-like tumor and stromal cells create physical and chemical barriers that prevent cytotoxic T lymphocytes from reaching tumor cells, while TGF-beta signaling itself directly dampens anti-tumor immune responses. Consistent with this biology, the researchers found that reducing SRPX2 enhanced the sensitivity of tumors to immune checkpoint inhibitors in preclinical models. Tumors that had previously resisted anti-PD-1 type therapy responded more effectively once the SRPX2-driven stromal and mesenchymal program was dismantled, accompanied by reduced mesenchymal abundance within the tumor microenvironment.

The clinical implications of these findings are considerable. For patients with microsatellite stable colorectal cancer, who derive little benefit from current immunotherapies, a strategy that combines checkpoint blockade with inhibition of the SRPX2–TGF-beta axis could, in principle, convert a cold, immune-excluded tumor into one that responds to immune attack. Moreover, because SRPX2 is a secreted protein, it is conceptually accessible to therapeutic antibodies or other extracellularly acting drugs, an advantage over intracellular targets that are harder to drug. The identification of a direct physical interaction between SRPX2 and TGFBR2 also provides a concrete structural starting point for the design of inhibitors that block this binding event, potentially achieving pathway suppression without the systemic toxicity that has limited broad TGF-beta blockade in clinical trials.

The study also carries diagnostic weight. Because multi-omics analysis identified SRPX2 as the leading correlate of aggressive progression and immunotherapy resistance, measuring SRPX2 levels in patient tumors could help stratify those most likely to fail standard therapies and guide enrollment into trials of SRPX2-targeted combinations. The work was conducted under ethical approval from the Institutional Research Ethics Committee of the Sun Yat-Sen University Cancer Center, with informed consent obtained from all participants whose clinical tissue specimens were used, and animal experiments were similarly reviewed and approved under institutional guidelines.

As with any preclinical discovery, the path from mechanistic insight to clinical application will require validation in larger patient cohorts and the development of clinically suitable SRPX2 inhibitors. Nevertheless, the study delivers a coherent and testable model: a secreted matrix-associated protein stabilizes the central receptor of the TGF-beta pathway, thereby coupling epithelial plasticity, extracellular matrix remodeling, and immune evasion into a single regulatory node. If that model holds in the clinic, targeting SRPX2 could offer one of the first rational opportunities to simultaneously attack metastasis and immunotherapy resistance in the colorectal cancer subsets that need it most.

Subject of Research: The role of SRPX2 in TGFBR2-mediated epithelial–mesenchymal transition, metastasis, and immune resistance in colorectal cancer

Article Title: SRPX2 aggravates tumor progression and immune resistance through TGFBR2-mediated epithelial–mesenchymal transition in colorectal cancer

Article References: Xi, C., Chenhong, W., Yuan, M., Dan, S., Chixiong, L., Yongbin, Z., Lixia, P., & Huali, L. (2026). SRPX2 aggravates tumor progression and immune resistance through TGFBR2-mediated epithelial–mesenchymal transition in colorectal cancer. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03411-5

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03411-5

Keywords: colorectal cancer, SRPX2, TGF-beta signaling, TGFBR2, epithelial-mesenchymal transition, metastasis, liver metastasis, immune checkpoint inhibitors, microsatellite stability, tumor microenvironment, extracellular matrix remodeling, immunotherapy resistance